Johnson & Johnson

09/27/2024 | Press release | Distributed by Public on 09/27/2024 11:02

DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not[...]